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M A J O R A R T I C L E
Ratio of Monocytes to Lymphocytes in
Peripheral Blood Identiﬁes Adults at Risk of
Incident Tuberculosis Among HIV-Infected
Adults Initiating Antiretroviral Therapy
Vivek Naranbhai,1,3 Adrian V. S. Hill,1,2 Salim S. Abdool Karim,3 Kogieleum Naidoo,3 Quarraisha Abdool Karim,3
George M. Warimwe,2 Helen McShane,2 and Helen Fletcher2
1Wellcome Trust Centre for Human Genetics and 2The Jenner Institute, Nufﬁeld Department of Medicine, University of Oxford, United Kingdom;
3Center for the AIDS Program of Research in South Africa, University of KwaZulu Natal, Durban
Background. Eight decades ago, the ratio of monocytes to lymphocytes (hereafter, the “ML ratio”) was noted to
affect outcomes of mycobacterial infection in rabbits. Recent transcriptomic studies support a role for relative pro-
portions of myeloid and lymphoid transcripts in tuberculosis outcomes. The ML ratio in peripheral blood is known
to be governed by hematopoietic stem cells with distinct biases.
Methods. The predictive value of the baseline ML ratio was modeled in 2 prospective cohorts of HIV-infected
adults starting cART in South Africa (primary cohort, 1862 participants; replication cohort, 345 participants). Inci-
dent tuberculosis was diagnosed with clinical, radiographic, and microbiologic methods per contemporary guide-
lines. Kaplan-Meier survival analyses and Cox proportional hazards modeling were conducted.
Results. The incidence rate of tuberculosis differed signiﬁcantly by baseline ML ratio: 32.61 (95% conﬁdence
interval [CI], 15.38–61.54), 16.36 (95% CI, 12.39–21.23), and 51.80 (95% CI, 23.10–101.71) per 1000 patient-years for
ML ratios of less than the 5th percentile, between the 5th and 95th percentiles, and greater than the 95th percentile,
respectively (P = .007). Neither monocyte counts nor lymphocyte counts alone were associated with tuberculosis. After
adjustment for sex, World Health Organization human immunodeﬁciency virus disease stage, CD4+ T-cell counts,
and previous history of tuberculosis, hazards of disease were signiﬁcantly higher for patients with ML ratios of less
than the 5th percentile or greater than the 95th percentile (adjusted hazard ratio, 2.47; 95% CI, 1.39–4.40; P = .002).
Conclusions. The ML ratio may be a useful, readily available tool to stratify the risk of tuberculosis and suggests in-
volvement of hematopoietic stem cell bias in tuberculosis pathogenesis.
Keywords. tuberculosis; HIV; combination antiretroviral therapy; monocytes; lymphocytes; ML ratio.
Tuberculosis is the leading cause of death in patients
commencing combination antiretroviral therapy (cART)
in sub-Saharan Africa [1–3], yet practical methods to strat-
ify risk in this population are lacking [4]. If individuals at
risk for tuberculosis could be accurately identiﬁed, they
could be targeted for preventive strategies such as che-
moprophylaxis. Risk factors for tuberculosis include
immunosuppression, diabetes mellitus, smoking, and
the presence of latent Mycobacterium tuberculosis in-
fection [5]. However, identifying individuals who have
latent M. tuberculosis infection or a high risk for devel-
oping tuberculosis is a major challenge; tuberculin skin
tests (TSTs) and the recently developed interferon γ–
release assays are poor at predicting which individuals
with latent infection will subsequently go on to develop
tuberculosis, particularly in human immunodeﬁciency
virus (HIV)–positive populations [6]. The need to iden-
tify groups at risk of tuberculosis is highlighted by the
fact that isoniazid preventive therapy is most effective
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among TST-positive patients [7, 8] as opposed TST-negative in-
dividuals [9].
Gene expression studies have identiﬁed biomarkers of active
tuberculosis that provide insight into immune mechanisms of
disease and may be useful for improving the diagnosis of tubercu-
losis [10, 11]. Fletcher et al recently used whole-transcriptome mi-
croarrays to identify correlates of risk of tuberculosis up to 2 years
before disease developed in infants who had been vaccinated with
BCG at birth (Fletcher et al, unpublished data). Relative abun-
dance of myeloid-speciﬁc gene transcripts and lymphoid-speciﬁc
transcripts at 10 weeks of age were associated with subsequent tu-
berculosis after stratifying for BCG responses. The observation
that the relative proportion of monocytes and lymphocytes may
be related to tuberculosis susceptibility is reminiscent of older
studies. Between 1921 and 1931, Florence Sabin and colleagues
found that numbers of monocytes were increased following ex-
perimental infection of rabbits with Mycobacterium bovis [12].
They and others reported that the ratio of lymphocytes to mono-
cytes in peripheral blood correlated with extent of disease in both
rabbits [13] and humans [14], although the numbers studied were
small and the strength of the conclusions that could be reached in
humans conceded to be modest. Finally, by experimentally reduc-
ing monocyte numbers in rabbits with a monocyte antiserum or
conversely increasing the number of monocytes with A-3 phos-
phatide and then challenging animals with M. bovis, they dem-
onstrated that reduced or elevated ratios of monocytes to
lymphocytes (hereafter, the “ML ratio”) were associated with
enhanced lethality of mycobacterial infection [15]. Lymphoid
cells are thought to be the major effector cells in tuberculosis
immunity and myeloid cells the major host cell for infection.
Therefore, the relative abundance may reﬂect a balance
between effector and target cells. Among infants with altered
ratios of myeloid transcripts to lymphoid transcripts in the
study by Fletcher et al, however, hematopoietic stem cell– and
inﬂammation-associated transcripts were also altered. There-
fore, an alternative explanation is that the relative abundance of
these cell types could be a marker of hematopoietic parameters
associated with tuberculosis. Collectively, these data support
the hypothesis that a high or a low ML ratio may be a correlate
of risk for tuberculosis. We evaluated this hypothesis in a
cohort of HIV-infected South African adults commencing com-
bination antiretroviral therapy (cART).
METHODS
Study Design and Setting
Data in this study were derived from several cohort studies or
clinical trials [16–19] conducted at the at the Centre for the
AIDS Program of Research in South Africa (CAPRISA) AIDS
Treatment (CAT) clinic in Vulindlela, rural KwaZulu Natal, or the
CAPRISA eThekwini clinic in Durban, KwaZulu Natal. In each
study, prospective follow-up with routine clinical assessments,
including speciﬁc assessment for tuberculosis and routine mea-
surement of monocyte and lymphocyte counts, was performed.
The UKZN Biomedical Research Ethic Committee approved
the use of the data from each study.
Participants Clinical Care, Tuberculosis Diagnosis, and Data
Sources
For the primary analysis participants were ambulatory, HIV-
seropositive, cART-naive adults older than 18 years who en-
rolled in care and treatment between April 2004 and April 2011
at the CAT clinic in Vulindlela, rural KwaZulu Natal [16]. Care
for HIV infection and/or tuberculosis was provided per the
South African treatment guidelines of that time [20–22]. Brief-
ly, patients who were clinically evaluated to have WHO stage IV
disease or had a CD4+ T-cell count <200 cells/µL were eligible
for commencement of a cART regimen comprising 2 nucleo-
side reverse-transcriptase inhibitors and 1 nonnucleoside reverse-
transcriptase inhibitor. During this period, the South African
guidelines did not support the routine use of isoniazid preven-
tive therapy for patients receiving cART. For this analysis, 1862
individuals who initiated cART and had at least 1 full blood
count measurement available before cART were included. At
enrollment, all individuals underwent clinical examination,
including clinical screening for tuberculosis and other opportu-
nistic infections. Individuals with active tuberculosis at enroll-
ment were excluded. Participants were clinically evaluated at
least twice before enrollment, and monthly after cART com-
mencement. During follow-up after cART initiation, individu-
als with symptoms and/or signs of tuberculosis were assessed
and received a diagnosis per South African guidelines, which
include clinical examination, sputum microscopy, and/or
culture and chest radiography as indicated [21].
The replication cohort was a cohort of cART-naive adults
who self-referred for care at the Prince Cyril Zulu Communica-
ble Diseases Centre, a chest clinic that provides care for the
eThekwini (Durban) municipality.
HIV-uninfected women enrolled in the CAPRISA004 trial
were included for analyses of the stability of the ML ratio [17].
Routine safety monitoring, including full blood count, was per-
formed at screening (0 months) and at 3, 12, and 24 months.
Individuals who had signs or symptoms of tuberculosis were
excluded.
For analyses of the impact of HIV acquisition and disease
progression, data from the CAPRISA002 study [19], a prospec-
tive cohort of HIV seroconverters, was used. In this study, full
blood counts were performed at weekly intervals for 3 weeks,
fortnightly until 3 months, monthly until 1 year after enroll-
ment, and every 3 months thereafter. Participants who started
cART were censored from this analysis.
For analyses of the impact of antituberculous therapy on the
ML ratio, data from the CAPRISA003/SAPiT trial were used [23].
In this randomized, controlled trial, participants with HIV
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infection and tuberculosis received antituberculous therapy fol-
lowed by cART at one of 3 time points deﬁned by randomiza-
tion. Full blood counts were performed before randomization
and monthly throughout follow-up.
In all cohorts, data were collected in real time during pro-
spective follow-up on standardized case report forms and cap-
tured electronically using the DataFax system (Clinical DataFax
Systems, Ontario, Canada) by at least 2 data encoders.
Full Differential Blood Counts
Full blood counts of peripheral blood collected in ethylenedi-
aminetetraacetic acid–containing tubes (Becton Dickinson)
were performed by one of 2 clinical diagnostic laboratories,
each using a 5-part differential hematology analyzer (Sysmex
Model XS, Hamburg, Germany). Full blood counts were
subject to strict quality assurance procedures, including twice-
daily high and low internal quality control, fortnightly quality
controls through the Thistle external quality assurance service
(Thistle QA, Johannesburg, South Africa), and annual quality
assurance as part of the College of American Pathologists QC
scheme. Both laboratories are accredited by the South African
National Accreditation System in accordance with international
standards ISO 17025:2005 and ISO 15189:2007.
Statistical Methods
To calculate the ML ratio, the absolute monocyte count was
divided by the absolute lymphocyte count. For the primary
analysis of tuberculosis incidence, a survival analysis was per-
formed. Study duration was calculated as the time from cART
initiation to the ﬁrst diagnosed episode of tuberculosis or
death, withdrawal from the study, transfer to another facility, or
last visit date (for patients remaining in follow-up), whichever
occurred ﬁrst. The log-rank test was used to compare survival
curves stratiﬁed by ML ratio. To test the association between
the ML ratio and tuberculosis incidence, a Cox proportional
hazards regression model was performed. Covariates included
in the model are given in the body text or tables. For the analy-
sis of continuous variables, the Kruskal-Wallis rank sum test
was used. All statistical tests were 2-sided, and a P value of < .05
was considered statistically signiﬁcant. Poisson approximations
were used to calculate conﬁdence intervals (CIs) for estimations
of the incidence rate. Bootstrapped estimates of the adjusted
HR across the ML ratio continuum were generated with the
boot package. Statistical analyses were performed in R (R Foun-
dation for Statistical Computing), using the following packages:
epiR, survival, date, and mfp.
RESULTS
We assessed whether the ML ratio, when evaluated before com-
mencement of cART, was predictive of the development of
tuberculosis during cART in a prospective cohort of 1862 HIV-
infected adults in South Africa. Baseline characteristics of this
cohort are detailed in Table 1. Notably, the cohort was predom-
inantly female (68.1%) and relatively young (mean age, 24.5
years), and 11.1% of individuals disclosed a previous episode of
treated tuberculosis. The median CD4+ T-cell count at baseline
was 120 cells/µL. The median follow-up for this cohort was 17
months but extended up to 7 years. The incidence of tuberculo-
sis, diagnosed per South African national guidelines, during follow
up was 18.79 cases per 1000 patient-years of treatment (95% CI,
14.71–23.66), consistent with comparable cohorts [24, 25].
Table 1. Baseline Characteristics of Adults Commencing Combination Antiretroviral Therapy in the Primary Study Cohort, Overall and
by Percentile Ranking of the Ratio of Monocytes to Lymphocytes Within the Cohort
Characteristic Overall (n = 1862) <5th (n = 93) 5th–95th (n = 1671) >95th (n = 98) Pa
Age, y, mean 24.5 24.5 24.6 22.6 .228
Female sex 1268 (68.1) 67 (72.04) 1150 (68.8) 52 (53.1) .002
Baseline CD4+ T-cell count,
cells/μL, median (IQR)
120 (61–180) 138 (102–182) 124 (65–182) 36 (17–98) <.0001
WHO HIV infection/disease stageb
1 355 (19.34) 26 (28.0) 320 (19.2) 9 (9.2) .004
2 490 (26.69) 22 (23.7) 448 (26.8) 20 (20.4) .28
3 831 (45.26) 41 (44.1) 739 (44.2) 51 (52.1) .38
4 160 (8.72) 3 (3.2) 139(8.3) 18 (18.4) .005
Past history of tuberculosisc 206 (11.11) 10 (10.75) 190 (11.37) 6 (6.12) .27
Data are no. (%) of subjects, unless otherwise indicated.
Abbreviations: HIV, human immunodeficiency virus; IQR, interquartile range; WHO, World Health Organization.
a By the Kruskal-Wallis test.
b A total of 26 patients were missing baseline WHO staging data.
c A total of 7 patients were missing baseline tuberculosis history data.
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ML Ratio Is Associated With Tuberculosis Among Adults
Starting cART
Based on Doan and Sabin’s observation that extremes of the
ML ratio were important for rabbit immunity to M. bovis [15],
we stratiﬁed participants into categories derived from the distri-
bution of the baseline pre-cART ML ratio in the entire cohort.
Participants with an ML ratio less than the 5th percentile,
between the 5th and 95th percentile, or greater than the 95th
percentile were similar in age and the proportion with a previ-
ous history of tuberculosis, but males, individuals with lower
CD4+ T-cell counts, and those with greater WHO staging
values were overrepresented in the group with the highest ML
ratio (>95th percentile) relative to the other 2 groups. This ob-
servation is concordant with expectations of individuals with
more severe lymphopenia having higher ML ratios (Table 1).
The ML ratio before cART initiation was associated with sig-
niﬁcantly different tuberculosis-free survival probabilities (P =
.007, by the log-rank test; Figure 1). After exclusion of cases di-
agnosed within 90 days of cART initiation, which may plausibly
represent unmasked tuberculosis, the association remained sig-
niﬁcant (P = .02, by the log-rank test). The overall incidence of
tuberculosis among individuals with an ML ratio less than the
5th percentile was 32.61 cases per 1000 patient years (95% CI,
15.38–61.54), and the overall incidence among individuals with
an ML ratio greater than the 95th percentile was 51.80 cases per
1000 patient years (95% CI, 23.10–101.71), compared with
16.36 per 1000 patient-years (95% CI, 12.39–21.23) for individ-
uals with an ML ratio between the 5th and 95th percentiles
(Table 2). Overall, the incidence of tuberculosis among individ-
uals with an ML ratio less than the 5th percentile or greater than
the 95th percentile was 39.44 (95% CI, 23.03–63.39), and the
HR was 2.40 (95% CI, 1.35–4.25; P = .003). Neither the mono-
cyte count nor lymphocyte count alone were predictive of tuber-
culosis on formal testing (Supplementary Figure 1 and Table 1).
To validate these results, the association between the baseline
pre-cART ML ratio and the risk of tuberculosis during cART
was assessed in a replication cohort of 345 adults commencing
cART at an urban treatment site implementing the same care
and treatment protocol as in the primary cohort. The overall
incidence of tuberculosis after cART commencement in this
cohort was 21.62 cases per 1000 patient-years (95% CI, 12.11–
35.92). Consistent with the ﬁnding in the primary cohort, pre-
treatment ML ratios that were less than the 5th percentile or
greater than the 95th percentile were independently associated
with a signiﬁcantly greater incidence and hazard of tuberculosis
(87.68 cases per 1000 patient-years [95% CI, 24.27–233.91] vs
17.64 cases per 1000 patient-years [95% CI, 9.05–31.29]; adjust-
ed HR, 3.94 [95% CI, 1.05–14.73]; P = .04).
To reﬁne estimates of the association between the ML ratio
and incident tuberculosis, we generated bootstrapped estimates
of effect across the ML ratio continuum (Figure 1B). These data
demonstrate a J-shaped association between ML ratio and
incident tuberculosis, with both low and high ML ratios associ-
ated with subsequent tuberculosis.
Association Between ML Ratio and Tuberculosis Risk Is Not
Explained by Confounding by Conventional Risk Factors for
Tuberculosis
Greater hazards of tuberculosis among those with the highest
ML ratios could potentially have been explained by known risk
Figure 1. Kaplan-Meier estimates of probability of tuberculosis-free
survival for individuals commencing combination antiretroviral therapy
(cART), by category of baseline ratio of monocytes to lymphocytes (ML
ratio; A). Bootstrapped hazard ratio (HR) estimates of tuberculosis across
the ML ratio continuum (B). HRs are adjusted for age, World Health Orga-
nization human immunodeﬁciency virus infection and disease stage, and
past history of tuberculosis. Each dot denotes 1 estimate, with the locally
weighted scatterplot smoothing curve overplotted.
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factors for tuberculosis in this population [24, 26] which
include a CD4+ T-cell of <100 cells/µL, WHO stage 3 or 4 HIV
infection or disease, male sex, and/or a past history of tubercu-
losis. To address these potential confounders, these covariates
were included in the Cox proportional hazards model (Table 2).
After adjustment for covariates, a pretreatment ML ratio of less
than the 5th or greater than the 95th percentile remained
independently associated with signiﬁcantly greater hazards of
tuberculosis (adjusted HR, 2.47; 95% CI, 1.39–4.40; P = .002).
Moreover, the association was consistently observed in analyses
stratiﬁed for each risk factor individually in the primary cohort
(Table 3).
To exclude the possibility that the effect of ML ratios on the
tuberculosis risk was mediated by modiﬁcation of HIV treat-
ment outcomes, we conﬁrmed that baseline ML ratios were not
associated with virological or immunological outcomes (per
2010 WHO criteria) 6 or 12 months after cART initiation in
the primary cohort (Supplementary Figure 2) or replication
cohort (data not shown).
ML Ratios Are Stable in HIV-Uninfected Women but Are
Increased by HIV Infection and Disease Progression and
Normalized by HIV or Tuberculosis Treatment
We assessed how the ML ratio is affected by changes in clinical
condition. Intuitively, the ML ratio is expected to vary following
HIV acquisition, tuberculosis, cART initiation, or tuberculosis
therapy because of changes in lymphocyte counts (Supplemen-
tary Figure 1C and D). Since the index takes into account
lymphocyte and monocyte values, and since the latter may
be independently regulated, variation of the ML ratio is of
interest.
The stability of the ML ratio was assessed among 790 healthy,
HIV-uninfected South African women who underwent routine
safety monitoring over 2 years while enrolled in a topical mi-
crobicide gel trial [1]. The ML ratio at visits 0 (enrollment), 3,
12, and 24 months were positively correlated (Spearman rho,
0.35–0.47; P < 5 × 10−7 for all comparisons; Figure 2A), and
there was no difference in the distribution of the ML ratio
between any 2 visits (Figure 2B). Even when monocyte and/or
Table 2. Cox Proportional Hazards Modeling of the Tuberculosis Risk Among 1862 Adults, by Percentile Ranking of the Ratio of
Monocytes to Lymphocytes Before Initiation of Combination Antiretroviral Therapy
Percentile Subjects, No.
Subjects Who Developed
Tuberculosis,
No./Patient-Years
Incidence Rate per
1000 Patient-Years
(95% CI)
Unadjusted
HR (95% CI) P
Adjusted
HR (95% CI)a P
5th–95th 1671 53/3238.8 16.36 (12.39–21.23) 1.00 (reference) . . . 1.00 (reference) . . .
<5th (0.1489619) 93 8/245.3 32.61 (15.38–61.54) 1.98 (.945–4.14) .071 2.09 (.99–4.39) .053
>95th (0.8746429) 98 7/135.1 51.80 (23.10–101.71) 2.60 (1.19–5.68) .017 2.63 (1.18–5.83) .018
<5th or >95th 191 15/380.5 39.44 (23.03–63.39) 2.40 (1.35–4.25) .003 2.47 (1.39–4.40) .002
Abbreviations: CI, confidence interval; HR, hazard ratio.
a Adjusted for sex, World Health Organization human immunodeficiency virus infection and disease stage, CD4+ T-cell count, and past history of tuberculosis.
Table 3. Stratiﬁed Cox Proportional Hazards Modeling of the Tuberculosis Risk Among Individuals With ML Ratios Above the 95th
Percentile or Below the 5th Percentile
Factor
Subjects,
Proportiona
Unadjusted
HR (95% CI) P
Adjusted HR
(95% CI)b P
Sex
Male 20/571 2.74 (.996–7.55) .051 2.71 (.966–7.60) .058
Female 48/1269 2.28 (1.13–4.57) .021 2.47 (1.22–4.99) .012
WHO HIV infection/disease stage 3 or 4 59/1656 2.30 (1.25–4.27) .008 3.18 (1.63–6.21) .0007
CD4+ T-cell count <100 cells/μL 28/656 3.52 (1.59–7.79) .002 3.36 (1.55–7.69) .002
Past history of tuberculosis
Yes 9/206 3.13 (.65–15.13) .16 3.45 (.70–16.9) .13
No 56/1656 2.31 (1.25–4.27) .008 2.40 (1.29–4.45) .005
Selection of strata was based on previously reported risk factors [24].
Abbreviation: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; WHO, World Health Organization.
a Data are no. of subjects who developed tuberculosis/no. at risk.
b Adjusted for sex, WHO HIV infection and disease stage, CD4+ T-cell count, and past history of tuberculosis (when that covariate is not the stratification variable).
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Figure 2. Ratios of monocytes to lymphocytes (ML ratios), monocyte counts, and lymphocyte counts among healthy human immunodeﬁciency virus–
uninfected woman. A, The correlation between the ML ratio at enrollment and 3, 12, and 24 months after enrollment among 790 participants. Results of
Spearman rank correlation are shown as rho and P values in the top right of each correlation plot. B, The overall stability of ML ratios in healthy individuals,
shown as box plots at each time point. The dotted horizontal lines denote the overall population 5th and 95th percentiles. Boxes show the 25th, 50th
(median), and 75th percentiles, whiskers denote the 25th percentile – [1.5 × interquartile range] and the 75th percentile + [1.5 × interquartile range], and
outliers are plotted as dots. C, ML ratios may be abnormal even if the monocyte or lymphocyte counts are normal. Monocyte and lymphocyte counts are
plotted on the x-axes and y-axes, respectively. Colors of data points denote the corresponding category of the ML ratio (5th–95th percentiles, >95th percen-
tile, and < 5th percentile). Dotted horizontal lines denote the 5th and 95th percentiles for lymphocyte counts. Dotted vertical lines denote the 5th and 95th
percentiles for monocyte counts. Abbreviation: NS, not signiﬁcant.
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lymphocyte counts were outside of their respective 5th–95th
percentiles, the majority (65.7%) of individuals had an ML
ratio between the 5th and 95th percentiles (both cell types in-
creased or decreased). Conversely, at 4.3% of visits the mono-
cyte and lymphocyte counts were between the 5th and 95th
percentiles, but the ML ratio was not (Figure 2C). These data
demonstrate that although the ML ratio is stable among healthy
individuals, about two thirds of individuals with altered
numbers (<5th or >95th percentile) of either cell type retain ap-
parently normal ML ratios, and conversely about 1 in 20 indi-
viduals with normal cell numbers may still have altered ML
ratios. The ML ratio captures information not adequately cap-
tured in the monocyte or lymphocyte counts alone.
Next, ML ratios were compared before and after HIV acqui-
sition in a cohort of 160 high-risk women prospectively fol-
lowed for HIV acquisition in several studies [1–3]. ML ratios
were similar between enrollment (median, 258 days before in-
fection; interquartile range [IQR], 126–432 days before infec-
tion) and the last time point before infection acquisition
(median, 97 days before infection; IQR, 43–180 days before in-
fection; Figure 3A). In contrast, ML ratios were signiﬁcantly in-
creased following HIV acquisition (median time of sampling,
29 days after infection; IQR, 15–54 days after infection; median
ML ratio, 0.193 before infection vs 0.256 after infection; P = 8.2
× 10−6; Figure 3A), consistent with postinfection lymphopenia.
Moreover, the distribution of ML ratios broadened with HIV
infection (Figure 3B). The ML ratio increased signiﬁcantly over
the course of HIV disease progression (Figure 3C and 3D; rho
for linear correlation with time after infection, 0.17; P < 5 ×
10−12). The ML ratio was not associated with the rate of HIV
disease progression, deﬁned as the time to achievement of a
CD4+ T-cell count of <350 cells/mL, death, or the need for
cART (data not shown).
The change in ML ratio with duration of cART was assessed
in a cohort of 2023 individuals who underwent screening and
commenced cART. The ML ratio was signiﬁcantly altered by
cART: over the ﬁrst 24 months of therapy, the median ML ratio
decreased to within the range observed for HIV-uninfected
healthy volunteers and was maintained at this level for up to 7
years (Figure 4).
Finally, the impact of tuberculosis therapy on the ML ratio
was evaluated. Among 642 adults with tuberculosis and HIV
infection who commenced antituberculosis therapy before
cART [4], antituberculosis therapy signiﬁcantly reduced ML
ratios (median ML ratio, 0.373 [IQR, 0.273–0.53] before treat-
ment vs 0.2753 [IQR, 0.203–0.376] after treatment; P =
3.32X10−14). Before tuberculosis therapy, 15% of individuals
(96/642) had ML ratios in the normal range for an HIV-
uninfected population, compared with 41.7% (189/642; median
therapy duration, 9 days) following tuberculosis therapy
(P < .0001).
DISCUSSION
The ability to stratify patients starting cART on the basis of
their risk of tuberculosis during follow-up is necessary for
targeting prevention interventions. Here, we demonstrate that
extremes in the ratio of peripheral blood monocytes to lympho-
cytes, but neither monocyte or lymphocyte counts alone, were
associated with an increased risk of incident tuberculosis over
several years. Our observation that the ML ratio is associated
with tuberculosis risk supports ﬁndings of recent microarray
studies in HIV-negative infants (Fletcher et al, unpublished
data) and extends ﬁndings made >80 years ago in rabbit models
of mycobacterial infection [15]. In more recent studies in cattle,
the ratio of monocyte-derived macrophages to lymphocytes has
been shown to correlate with inhibition of mycobacterial growth
in vitro [27, 28]. The observation that risk is higher among indi-
viduals with either low or high ML ratios adds evidence to
support recent ﬁndings that extremes of immunity are associated
with tuberculosis [29, 30], as differences in the ratio of myeloid
transcripts to lymphoid transcripts in infants were associated
with differences in inﬂammatory gene expression (Fletcher et al,
unpublished data). Collectively, the historical small-animal
studies, recent microarray data, and these human studies demon-
strate that the ML ratio may be an easily measured predictive bi-
omarker of tuberculosis. This ratio could herald a previously
unknown pathophysiologic driver of tuberculosis.
Whether the ML ratio is causatively involved in tuberculosis
or simply reﬂects underlying traits that affect tuberculosis risk
will require further study. It is likely that the ML ratio captures
underlying differences in the immune microenvironment, as
has been implied by its prognostic value in inﬂuenza [31] and
malaria. Recent studies in mice [32] and humans [33] have
shown that subsets of hematopoietic stem cells have distinct
biases in the ratio of myeloid and lymphoid cells they give rise
to [34, 35]. We speculate that differences in the proportions of
myeloid-biased, balanced, or lymphoid-biased hematopoietic
stem cells may underlie the peripheral differences in the ML
ratio and that the ontogeny of monocytes and lymphocytes, re-
ﬂected in their ratio, may affect their ability to respond to my-
cobacterial infection. Recent studies have demonstrated that
mycobacterial infection may alter hematopoiesis [36] or di-
rectly infect bone marrow mesenchymal stem cells [37]. There-
fore, it is plausible that latent or prior M. tuberculosis infection
may alter hematopoietic stem cells such that the peripheral ML
ratio is altered. In support of this is the observation that in the
microarray studies, alongside the ratio of myeloid transcripts to
lymphoid transcripts being a signature of risk, transcripts sug-
gesting activation/quiescence of hematopoietic stem cells were
more prevalent among infants who developed tuberculosis. Al-
ternatively, the ML ratio and underlying hematopoietic stem
cell activity may be epiphenomena, and the ML ratio may be a
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marker of where along the spectrum [38] of tuberculosis between
latent and active disease an individual is, consistent with hypoth-
esis ﬁrst proposed in 1935 by Kato [39]. Further work to explore
the pathophysiological involvement of the ML ratio in tuberculo-
sis may yield new pathways to modify or prevent disease.
The clinical usefulness of the observation that the ML ratio is
related to prospective risk of tuberculosis is promising but will
beneﬁt from extension and validation in non–tuberculosis-
endemic regions, among children, and in HIV-negative adults.
In particular, the diagnostic performance of the ratio and the
development of standards or diagnostic thresholds require at-
tention. Evaluation of whether the ML ratio is associated with
other disorders, as is suggested by recent studies in inﬂuenza [31]
and malaria [40], is also necessary. Moreover, the question of
Figure 3. The impact of human immunodeﬁciency virus (HIV) acquisition and disease progression on ratios of monocytes to lymphocytes (ML ratios). A,
The ML ratio is stable before infection among 160 women who acquired HIV but is signiﬁcantly increased by HIV acquisition. Boxes show the 25th, 50th
(median), and 75th percentiles, whiskers denote the 25th percentile – [1.5 × interquartile range] and the 75th percentile + [1.5 × interquartile range], and
outliers are plotted as dots. B, The distribution of ML ratios is broadened by HIV acquisition. C, ML ratios over the course of HIV acquisition are variable
but increase overall. Data are shown as a scatterplot showing all ML measures over time among HIV acquirers. The black line is a smoothed curve comput-
ed by locally weighted scatterplot smoothing. Horizontal lines denote the 5th and 95th percentile for ML ratios in HIV-uninfected healthy individuals in red
and blue, respectively. D, ML ratios over the course of HIV infection increase signiﬁcantly with disease progression. Boxes show the 25th, 50th (median),
and 75th percentiles, whiskers denote the 25th percentile – [1.5 × interquartile range] and the 75th percentile + [1.5 × interquartile range], and outliers are
plotted as dots. Horizontal lines denote the 5th and 95th percentile for ML ratios in HIV-uninfected healthy individuals in red and blue, respectively.
Monocyte: Lymphocyte Ratio and Tuberculosis Risk • JID 2014:209 (15 February) • 507
whether ML ratios during cART continue to offer predictive
value will need speciﬁc evaluation. Since neither the ML ratio,
TST, nor interferon γ–release assays reliably detect all individu-
als at risk for tuberculosis, their combined use may need to be
explored for its potential in risk stratiﬁcation.
Although we observed that higher ML ratios were associated
with tuberculosis, it is possible that tuberculosis was present
but not diagnosed at the time of enrollment (reverse causation).
But the observation that the association appears to hold out for
several years, and is present even excluding early tuberculosis
diagnoses, suggests that undiagnosed tuberculosis at enrolment
does not account for the association.
An important potential limitation of this study is that this
was a secondary data analysis study, so it is plausible that there
may have been misclassiﬁcation of the tuberculosis diagnosis if
tuberculosis was not speciﬁcally and prospectively assessed. But
the data used here were obtained during the conduct of pro-
spective studies in which assessment for any clinical disorder,
particularly tuberculosis, was performed. The diagnostic algo-
rithm for tuberculosis used in these studies followed the nation-
al South African guidelines, and so the diagnostic procedures
in this study approximate those in clinical settings, which are
known to suffer impaired sensitivity for incident tuberculosis.
A further limitation of this study is that participants did not
have TSTs or interferon γ–release assays performed. Finally, at
the time of clinical assessment, although clinicians were not
blinded to the full blood count, they were not aware of this hy-
pothesis, thus diminishing diagnostic bias.
Among patients starting cART, the ability to predict the risk
of tuberculosis may facilitate targeted interventions such as vac-
cination, treatment for latent M. tuberculosis infection to
prevent tuberculosis ,or closer clinical monitoring to diagnose
tuberculosis earlier. The ML ratio may be a useful, readily avail-
able tool to stratify risk of tuberculosis and provide a new
insight into tuberculosis pathogenesis.
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